Abstract
An age-appropriate questionnaire (GASP-Q) was used to assess the frequency and severity of the gastroesophageal reflux disease (GERD) symptoms: abdominal/belly pain, chest pain/heartburn, pain after eating, nausea, burping/belching, vomiting/regurgitation, choking when eating, and difficulty swallowing, in adolescents age 12 to 16 years. The primary objective was to compare the mean composite symptom score (CSS) at week 8 with baseline after treatment with 20 or 40 mg of pantoprazole. Statistically significant (p < 0.001) improvement in CSS occurred in both groups. Safety was comparable between the 2 groups. Pantoprazole was safe, well tolerated, and effective in reducing symptoms of GERD in adolescents.
Publication types
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage
-
2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*
-
Adolescent
-
Aluminum Hydroxide
-
Antacids
-
Anti-Ulcer Agents / administration & dosage
-
Anti-Ulcer Agents / therapeutic use*
-
Child
-
Double-Blind Method
-
Drug Combinations
-
Female
-
Gastroesophageal Reflux / drug therapy*
-
Humans
-
Magnesium Hydroxide
-
Male
-
Pantoprazole
-
Simethicone
-
Surveys and Questionnaires
Substances
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Antacids
-
Anti-Ulcer Agents
-
Drug Combinations
-
aluminum hydroxide, magnesium hydroxide, simethicone drug combination
-
Aluminum Hydroxide
-
Simethicone
-
Pantoprazole
-
Magnesium Hydroxide